Evidence map›Paper›PMID 26878073›Full record

ArticleJournal of virus eradication

The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis.

Kenneth A Freedberg, Cristina Possas, Steven Deeks, Anna Laura Ross, Katherine L Rosettie, Michele Di Mascio, Chris Collins, Rochelle P Walensky, Yazdan Yazdanpanah

Abstract read
In one paragraph

Article in Journal of virus eradication. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Modeling Kick-Kill Strategies toward HIV Cure.Frontiers in immunology · 2017
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kenneth A FreedbergDivisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA, USA; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Cristina PossasOswaldo Cruz Foundation, Evandro Chagas National Institute of Infectious Diseases and Bio-Manguinhos, Rio de Janeiro, Brazil.
Steven DeeksUniversity of California San Francisco Department of Medicine, San Francisco General Hospital, San Francisco, CA, USA; Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA; American Society for Clinical Investigation, Ann Arbor, MI, USA; Department of Health and Human Services, National Institutes of Health, Bethesda, MD, USA.
Anna Laura RossInternational and Scientific Relations Office, ANRS, Paris, France; International AIDS Society, Geneva, Switzerland.
Katherine L RosettieDivisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Michele Di MascioDivision of Clinical Research, National Institute of Allergy and Infectious Diseases, The National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Chris CollinsCommunity Mobilization Division, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
Rochelle P WalenskyDivisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA, USA; Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA.
Yazdan YazdanpanahINSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France; AP-HP, Hôpital Bichat, Services de Maladies Infectieuses et Tropicales, F-75018 Paris, France.

Funding

Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR01AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI REDDY, KRISHNA P · 2011 to 2024
$6.8M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR37AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALENSKY, ROCHELLE P. · 2015 to 2019
$3.8M
HIV cure studies: risk, risk perception, and ethicsR01AI114617 · NIAID · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI EYAL, NIR · 2015 to 2018
$3.2M
NIAID NIH HHS R01 AI058736NIAID NIH HHS R01 AI093269NIAID NIH HHS R01 AI114617
6 · The paper itself

Abstract

The research agenda towards an HIV cure is building rapidly. In this article, we discuss the reasons for and methodological approach to using mathematical modeling and cost-effectiveness analysis in this agenda. We provide a brief description of the proof of concept for cure and the current directions of cure research. We then review the types of clinical economic evaluations, including cost analysis, cost-benefit analysis, and cost-effectiveness analysis. We describe the use of mathematical modeling and cost-effectiveness analysis early in the HIV epidemic as well as in the era of combination antiretroviral therapy. We then highlight the novel methodology of Value of Information analysis and its potential role in the planning of clinical trials. We close with recommendations for modeling and cost-effectiveness analysis in the HIV cure agenda.

Indexed as

cost-effectivenesscureHIV/AIDSmathematical modeling

Identifiers

PMID26878073
PMCPMC4748959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.